SEARCH:   Advanced

Blood, 15 August 2007, Vol. 110, No. 4, pp. 1370-1378. Prepublished online as a Blood First Edition Paper on April 13, 2007; DOI 10.1182/blood-2007-03-081497. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-03-081497v1 110/4/1370    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Smith-Berdan, S. Articles by Christensen, J. L. Search for Related Content PubMed PubMed Citation Articles by Smith-Berdan, S. Articles by Christensen, J. L. Related Collections Immunobiology Transplantation Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Reversal of autoimmune disease in lupus-prone New Zealand black/New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cells Stephanie Smith-Berdan1, Daphne Gille1, Irving L. Weissman2, and Julie L. Christensen1 1 Cellerant Therapeutics, San Carlos, CA; and 2 Stanford University School of Medicine, Palo Alto, CA Patients with severe systemic lupus erythematosus (SLE) refractory to conventional treatment are candidates for autologous hematopoietic stem cell (HSC) transplantation if the intent is to reset the immunologic clock. These patients might be candidates for allotransplantation with (SLE)-resistant major histocompatibility complex (MHC) haplotype-matched HSC if partial or complete replacement of an autoimmune-prone system is the intent. Using lupus-prone New Zealand black x New Zealand white (NZBW) mice, we investigated the use of highly enriched, haplomismatched, allogeneic HSC to prevent development of or to treat established autoimmune pathology. Young NZBW mice receiving purified allogeneic HSC transplants had improved survival, decreased proteinuria, circulating immune complexes, and autoantibodies to nuclear antigens than did untreated mice or mice given NZBW HSCs. NZBW mice with established lupus-like disease that received nonmyeloablative conditioning and transplants of (MHC) haplomismatched allogeneic HSCs also had greatly increased overall survival. Mice that received transplants exhibited stabilization or reversal of their lupus symptoms; stabilized or decreased proteinuria, and a lower frequency of elevated circulating immune complexes or autoantibodies than did control mice. Induction of durable mixed chimerism by transplantation of purified allogeneic HSCs after nonmyeloablative conditioning has the potential to reverse symptoms of established NZBW lupus. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: O. Jones, A Lacson, X Zeng, J. Jones, K Katti, R. Cahill, and A. Ahmed Long-term follow-up after non-myeloablative transplant of bone and marrow in BXSB mice Lupus, August 1, 2009; 18(9): 813 - 821. [Abstract] [PDF] L. Sun, K. Akiyama, H. Zhang, T. Yamaza, Y. Hou, S. Zhao, T. Xu, A. Le, and S. Shi Mesenchymal Stem Cell Transplantation Reverses Multiorgan Dysfunction in Systemic Lupus Erythematosus Mice and Humans Stem Cells, June 1, 2009; 27(6): 1421 - 1432. [Abstract] [Full Text] [PDF] A Tyndall Cellular therapy of systemic lupus erythematosus Lupus, April 1, 2009; 18(5): 387 - 393. [Abstract] [PDF] N. Li, D. Zhao, M. Kirschbaum, C. Zhang, C.-L. Lin, I. Todorov, F. Kandeel, S. Forman, and D. Zeng HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen PNAS, March 25, 2008; 105(12): 4796 - 4801. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020